|
|
Caspian Journal of Neurological Sciences، جلد ۳، شماره ۸، صفحات ۴۶-۵۳
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease |
|
| چکیده انگلیسی مقاله |
The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells. Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells. The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies. |
|
| کلیدواژه‌های انگلیسی مقاله |
|
|
| نویسندگان مقاله |
دیوید lyman | david lyman
mph retired, department of family medicine, university of tennessee, jackson, tennessee; dlymanmdmph@gmail.com
|
|
| نشانی اینترنتی |
http://cjns.gums.ac.ir/browse.php?a_code=A-10-32-65&slc_lang=en&sid=en |
| فایل مقاله |
اشکال در دسترسی به فایل - ./files/site1/rds_journals/1782/article-1782-383977.pdf |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
تخصصی |
| نوع مقاله منتشر شده |
مروری |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|